Search

for
Search:

GlossaryUstekinumab

monoclonal antibody treating autoimmune diseases by targeting interleukins

Ustekinumab, marketed as Stelara, is a monoclonal antibody used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn's disease. It works by targeting specific proteins in the immune system (interleukin-12 and interleukin-23) to reduce inflammation and abnormal immune responses.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 249 results

research Incidence of Serious Infectious Events with Methotrexate Treatment: Meta-Analysis of Randomized Controlled Trials

February 2010 in “Journal of The American Academy of Dermatology”

Methotrexate treatment for rheumatoid arthritis has a serious infection rate of about two per 100 patient-years.

research Molecular Genetic Dissection of ILVEN Leads to Successful Targeted Therapy

September 2019 in “Journal of Investigative Dermatology”

Targeted therapy with Ustekinumab significantly improved a skin condition called ILVEN, which is caused by mutations in the CARD14 gene.

research Effective Use of Ustekinumab in a Patient with Concomitant Psoriasis, Vitiligo, and Alopecia Areata

20 citations , November 2017 in “JAAD case reports”

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

research Scattered Skin Eruptions in a Patient With Inflammatory Bowel Disease

1 citations , February 2021 in “Gastroenterology”

A woman with inflammatory bowel disease improved after treatment with ustekinumab for a rare skin condition associated with her disease.

research A Case of Steatocystoma Multiplex in a Psoriatic Patient During Treatment with Anti-IL-12/23

2 citations , January 2020 in “Skin Appendage Disorders”

Ustekinumab treatment may reveal a genetic tendency for steatocystoma multiplex in psoriasis patients.

View more "ustekinumab" in research →

Community Join

0 / 0 results

— no results